DVA Stock Overview
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD).
Price History & Performance
|Historical stock prices|
|Current Share Price||US$96.91|
|52 Week High||US$136.48|
|52 Week Low||US$96.75|
|1 Month Change||-6.13%|
|3 Month Change||-25.89%|
|1 Year Change||-11.78%|
|3 Year Change||45.99%|
|5 Year Change||51.16%|
|Change since IPO||2,278.15%|
Recent News & Updates
DaVita (NYSE:DVA) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Does DaVita (NYSE:DVA) Deserve A Spot On Your Watchlist?
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
|DVA||US Healthcare||US Market|
Return vs Industry: DVA underperformed the US Healthcare industry which returned 19.1% over the past year.
Return vs Market: DVA underperformed the US Market which returned 21.3% over the past year.
|DVA Average Weekly Movement||4.6%|
|Healthcare Industry Average Movement||6.3%|
|Market Average Movement||6.0%|
|10% most volatile stocks in US Market||15.0%|
|10% least volatile stocks in US Market||2.3%|
Stable Share Price: DVA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: DVA's weekly volatility (5%) has been stable over the past year.
About the Company
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
DaVita Fundamentals Summary
|DVA fundamental statistics|
Is DVA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DVA income statement (TTM)|
|Cost of Revenue||US$7.97b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||9.66|
|Net Profit Margin||8.50%|
How did DVA perform over the long term?See historical performance and comparison
Is DaVita undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: DVA ($96.91) is trading below our estimate of fair value ($208.16)
Significantly Below Fair Value: DVA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: DVA is good value based on its PE Ratio (10x) compared to the US Healthcare industry average (21.5x).
PE vs Market: DVA is good value based on its PE Ratio (10x) compared to the US market (17.1x).
Price to Earnings Growth Ratio
PEG Ratio: DVA is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: DVA is overvalued based on its PB Ratio (8.6x) compared to the US Healthcare industry average (2.9x).
How is DaVita forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DVA's forecast earnings growth (5.2% per year) is above the savings rate (2%).
Earnings vs Market: DVA's earnings (5.2% per year) are forecast to grow slower than the US market (14.3% per year).
High Growth Earnings: DVA's earnings are forecast to grow, but not significantly.
Revenue vs Market: DVA's revenue (4.1% per year) is forecast to grow slower than the US market (10.1% per year).
High Growth Revenue: DVA's revenue (4.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DVA's Return on Equity is forecast to be very high in 3 years time (113%).
How has DaVita performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DVA has high quality earnings.
Growing Profit Margin: DVA's current net profit margins (8.5%) are higher than last year (7.2%).
Past Earnings Growth Analysis
Earnings Trend: DVA's earnings have declined by 5.9% per year over the past 5 years.
Accelerating Growth: DVA's earnings growth over the past year (18.3%) exceeds its 5-year average (-5.9% per year).
Earnings vs Industry: DVA earnings growth over the past year (18.3%) underperformed the Healthcare industry 32.5%.
Return on Equity
High ROE: Whilst DVA's Return on Equity (44.2%) is outstanding, this metric is skewed due to their high level of debt.
How is DaVita's financial position?
Financial Position Analysis
Short Term Liabilities: DVA's short term assets ($3.8B) exceed its short term liabilities ($2.4B).
Long Term Liabilities: DVA's short term assets ($3.8B) do not cover its long term liabilities ($12.5B).
Debt to Equity History and Analysis
Debt Level: DVA's net debt to equity ratio (274.9%) is considered high.
Reducing Debt: DVA's debt to equity ratio has increased from 145% to 313.8% over the past 5 years.
Debt Coverage: DVA's debt is well covered by operating cash flow (21.8%).
Interest Coverage: DVA's interest payments on its debt are well covered by EBIT (6.6x coverage).
What is DaVita current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DVA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DVA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Javier Rodriguez (50 yo)
Mr. Javier J. Rodriguez serves as Independent Director at Gilead Sciences, Inc. since June 15, 2020. He has been Chief Executive Officer and Executive Director of DaVita Inc. since June 1, 2019. Mr. Rodrig...
CEO Compensation Analysis
Compensation vs Market: Javier's total compensation ($USD73.43M) is above average for companies of similar size in the US market ($USD11.11M).
Compensation vs Earnings: Javier's compensation has increased by more than 20% in the past year.
Experienced Management: DVA's management team is seasoned and experienced (5.5 years average tenure).
Experienced Board: DVA's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
DaVita Inc.'s employee growth, exchange listings and data sources
- Name: DaVita Inc.
- Ticker: DVA
- Exchange: NYSE
- Founded: 1994
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$9.875b
- Shares outstanding: 101.90m
- Website: https://www.davita.com
Number of Employees
- DaVita Inc.
- 2000 16th Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/30 00:10|
|End of Day Share Price||2021/11/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.